HALOZYME THERAPEUTICS
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and di... spersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need.
HALOZYME THERAPEUTICS
Industry:
Biotechnology Marketing Medical
Founded:
1998-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.halozyme.com
Total Employee:
101+
Status:
Active
Contact:
858.794.8889
Email Addresses:
[email protected]
Total Funding:
245 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Tag Manager WordPress Wordpress Plugins Organization Schema IPv6 ReCAPTCHA Cloudflare JS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Dice Therapeutics
Dice Therapeutics develops a transformative platform designed for the discovery of novel small molecules.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company that discovers and develops precise medicines for human disease.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-04-13 | Antares Pharma | Antares Pharma acquired by Halozyme Therapeutics | 960 M USD |
Investors List
Janssen Biotech
Janssen Biotech investment in Post-IPO Equity - Halozyme Therapeutics
arGEN-X
arGEN-X investment in Post-IPO Equity - Halozyme Therapeutics
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - Halozyme Therapeutics
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - Halozyme Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Halozyme Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Halozyme Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Halozyme Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Halozyme Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-02 | Halozyme Appoints New Chief Financial Officer |
| 2020-02-24 | Halozyme Announces CFO Transition |
Official Site Inspections
http://www.halozyme.com Semrush global rank: 3.28 M Semrush visits lastest month: 5 K
- Host name: 104-237-144-180.ip.linodeusercontent.com
- IP address: 104.237.144.180
- Location: Newark United States
- Latitude: 40.739
- Longitude: -74.1697
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07175
More informations about "Halozyme Therapeutics"
About Us | Halozyme
Dec 30, 2023 At Halozyme, we are focused on innovative and disruptive solutions that provide new therapeutic options that could significantly improve the patient experience. We also support our partners with our drug delivery …See details»
Halozyme - Wikipedia
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. See details»
Responsibility - Halozyme
Halozyme has established a compliance reporting mechanism intended to supplement, not replace, other channels for communicating questions or concerns within the organization. A company independent of Halozyme staffs …See details»
Halozyme, Inc. - LinkedIn
Halozyme, Inc. | 19,499 followers on LinkedIn. At Halozyme we continuously push the pace of innovation. | Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly ...See details»
Halozyme Therapeutics, Inc. - Investor Relations
Nov 18, 2024 Contact Us. Tram Bui Vice President, Investor Relations & Corporate Communications 609-359-3016 [email protected] [email protected] [email protected]See details»
Halozyme Therapeutics - Crunchbase Company Profile …
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is …See details»
Halozyme Therapeutics, Inc. (HALO) - Yahoo Finance Canada
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, …See details»
Halozyme Therapeutics, Inc. - Events & Presentations - Presentations
Oct 31, 2024 Contact Us. Tram Bui Vice President, Investor Relations & Corporate Communications 609-359-3016 [email protected] [email protected] [email protected]See details»
Halozyme Therapeutics And Pfizer Enter Into A Collaboration To …
Dec 21, 2012 Halozyme Therapeutics, Inc. (HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. (PFE) for the purpose of …See details»
Halozyme to Acquire Antares Pharma to Create a …
Apr 13, 2022 Halozyme Contacts: Investors: Dawn Schottlandt / Claudia Styslinger Argot Partners 212-600-1902 [email protected] [email protected] Media: Eric Brielmann / Kelly Sullivan / Amy Feng / Caroline LipeSee details»
ENHANZE Drug Delivery Technology - Halozyme
Halozyme’s ENHANZE ® drug delivery technology, which is a proprietary, validated rHuPH20 enzyme paired with our unparalleled expertise in subcutaneous (SC) drug development, has …See details»
Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10, 2024 Halozyme's (NASDAQ:HALO) ENHANZE technology, which facilitates "rapid high-dose, high-volume subcutaneous drug delivery," has transformed the company into a …See details»
ViiV Healthcare and Halozyme enter global collaboration and …
London and San Diego, 22 June 2021 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as …See details»
Halozyme seeks to buy Evotec - Chemical & Engineering News
5 days ago Halozyme, a California firm that engineers under-the-skin injectable versions of intravenous drugs, is looking to buy the German pharmaceutical services company Evotec. …See details»
Bristol-Myers Squibb and Halozyme Enter Global Collaboration …
Sep 14, 2017 Bristol-Myers Squibb is Committed to Enhancing Patient Care Through Delivery of Cancer Treatments by Subcutaneous Injection Halozyme to Receive $105 Million Upfront …See details»
Halozyme: How This Small Biotech Is Getting Under Your Skin
Jul 3, 2024 Halozyme stock broke out of a cup-with-handle base with a buy point at 42.64 on May 8. Shares are now in a profit-taking zone, MarketSurge chart analysis shows. Savvy …See details»
2022 Environmental, Social & Governance Report - Halozyme
Enzyme rHuPH20, Halozyme’s commercially validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched …See details»
Halozyme Therapeutics to Host Presentations at Investor …
3 days ago SAN DIEGO, Nov. 27, 2024 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that members of its executive leadership team will …See details»
Insights Value Series: Introduction | Halozyme
We want to provide some insight into our company’s values in an ongoing series on Halozyme’s Insights webpage. This series is an opportunity to continue to build our connectivity and …See details»
Halozyme: 7 Years Of Royalty Bliss Coming; Afterwards, Questions …
Halozyme is also currently profitable under its new structure posting Q3 EPS of .25c and estimates for 2020 are for EPS of .90c. CEO Helen Torley has on multiple occasions indicated …See details»